CD101 and vulvovaginal candidiasis: CD101 is presently in phase 2 clinical development as a once-weekly i.v. formulation that provides high plasma exposure for treating candidemia (RADIANT trial [ClinicalTrials.gov identifier NCT02733432]) and as a topical formulation for treating acute and recurrent vulvovaginal candidiasis (STRIVE trial [ClinicalTrials.gov identifier NCT02734862]).